Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 145Kidney Neoplasms 42Neoplasms 39Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 31Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Carcinoma 10Stomach Neoplasms 8Neuroendocrine Tumors 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Adenoma, Islet Cell 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Clear-cell metastatic renal cell carcinoma 6

Interventions

fluciclovine F-18 2relatlimab 1pembrolizumab 1enfortumab vedotin 1darolutamide 1Watchful Waiting 1Transurethral Resection of Prostate 1Sunitinib 1Radiotherapy 1Radiation Dose Hypofractionation 1Pregnancy Tests 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1Human Papillomavirus DNA Tests 1Gemcitabine 1Fluorouracil 1Colposcopy 1Cisplatin 1Biopsy 1Acetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Diseases × Sunitinib × Clear all
NCT00912912 2016-04-15

Sunitinib Malate in Refractory Germ Cell Tumors

M.D. Anderson Cancer Center

Phase 2 Terminated
5 enrolled 6 charts

Urogenital Diseases, Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡